Hemogenyx Pharmaceuticals Reports First Half Results with Increased Loss
Hemogenyx Pharmaceuticals Plc reported a loss before taxation of £6,557,736 for the first half of the year ending June 30, 2026. This represents an increase from the previous year's loss of £5,006,415 in 2025. The company attributed this to higher operating costs, which rose to £6,481,401 compared to £4,886,532 a year earlier. Despite the increased losses, Hemogenyx maintained cash and cash equivalents of £4,584,849 as of June 30. The financial results highlight ongoing operational challenges for the company amid its development efforts in pharmaceuticals.
